# McKesson share price today (McKesson Corporation, MCK)

> McKesson Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. MCK · Healthcare · Medical Distribution · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/mck

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from fewer quarters than usual
- Price: $1,069 (+25.5% in a year)
- P/E: 28.5× (higher than 83% of the last 4.6 years)
- Revenue (Jun 2026): $105 B (+7.7% on a year ago)
- Profit (Jun 2026): $1.0 B (+24.2% on a year ago)
- Operating margin: 1.3% (flat on a year ago)
- ROE: −611%, FY26
- ROIC: 31.7%, against a 5.5% cost of capital: +26.2 points

The main question: results are strong, and the P/E is higher than 83% of its own history. ## What is the McKesson share price today? McKesson Corporation's share price was $1,069 at the close on 4 November 2026. It has been rising for 17 weeks. That is 23.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $736 and $1,069, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 10 years the share price moved +455% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does McKesson pay? McKesson Corporation paid $3.28 per share over the last four reported quarters. The most recent declaration was $0.82 for Jun 2026. At today's price of $1,069 that is a yield of 0.31%, based on dividends already paid, not a forecast. ## Which stock lists is McKesson on? McKesson is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is McKesson profitable? McKesson Corporation earned $1.0 B of net profit in the Jun 2026 quarter, +24.2% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was $5.1 B. Over 4 years profit has grown 41.1% a year on average. That is 1.0% of the quarter's revenue. The same quarter a year earlier earned $831 M. For the full year, FY26 profit was $5.1 B (+46.5% on the year before). Why profit moved: revenue changed +7.7% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +101.5% and revenue +8.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does McKesson make, and is it growing? McKesson Corporation reported $105 B of revenue in the Jun 2026 quarter, +7.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 11.2% a year on average. The last full year, FY26, came in at $403 B. The last four reported quarters add to $411 B. FY26 revenue was $403 B, +12.4% on the year before. Recent pace: the last four quarters grew +8.8% on average, against 11.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +8.8%, against +14.5% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +58.1%, against +30.3% a year (accelerating). ## How much of every $100 of sales does McKesson keep? McKesson Corporation's operating margin was 1.3% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.4% and 1.6%. The latest quarter is below every full year in that period. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is McKesson's profit turning into cash? Over the last 3 years, 141% of McKesson Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $6.2 B of operating cash against $5.1 B of profit. After $436 M of spending on assets, $5.7 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does McKesson's cash go? McKesson Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.4 B on assets over the last 3 years. Averaged over those years that is 0.1% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.4 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is McKesson's P/E ratio, and how does it compare with its own history? McKesson Corporation's P/E is 28.5×, near the high end of its own history: higher than 83% of past readings. Its usual P/E (the middle reading) is 25.1×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +49.2% while the price moved +25.5%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +33.2% a year; about +13.9% a year came from earnings growth and about +19.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the McKesson business getting better or worse? McKesson Corporation's business is getting better. Profit growth hit its low 7 quarters ago at −20.1% and has recovered to +58.1%. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: a lasting rise from a low is what this page is built to show. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does McKesson earn on its capital? McKesson Corporation earned a ROE of −611% in FY26. Its return on capital used (ROIC) is 26.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 1.3% net margin and 4.90× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 1.3% net margin × 4.90× asset turnover × −98.71× leverage (assets divided by equity) ≈ −628.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 31.7% − 5.5% = +26.2 percentage points. The 5.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 31.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 35.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does McKesson have too much debt? McKesson Corporation's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −4.25 in FY22 to −10.53 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the McKesson shareholding pattern? 2.0% of McKesson Corporation's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 2.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is McKesson from balance-sheet trouble? For McKesson Corporation, the Z-score is 5.81. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.81 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does McKesson rank in its industry? 79.9 out of 100, rank 1 of 8 in Medical Distribution, with 85% of the evidence available. McKesson Corporation scores 79.9 out of 100 against the 8 companies it is compared with in Medical Distribution, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 25.7 + 18.2 + 16 + 20 = 79.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is McKesson compared with? McKesson ranks 1 of 8 Medical Distribution companies on the 4-Factor Sector Score, with 79.9 out of 100. 1. McKesson Corporation this page MCK · leader · Most evidence points up · 85% evidence 79.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 8.8% · Profit 58.1% · Operating margin change 0 points · 95% evidence Capital efficiency 18.2/25 · ROCE 36.7% · Operating margin 1.3% · 76% evidence Valuation 16.0/20 · P/E 19.3× · PEG 0.39 · 65% evidence Relative strength 20.0/20 · Lead over its industry 12.9% · Lead over S&P 500 16.2% · 1 year 25.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.7 + 18.2 + 16 + 20 = 79.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) COR · breaking out · Evidence leans up · 85% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 5.1% · Profit 38.4% · Operating margin change 0.2 points · 95% evidence Capital efficiency 14.9/25 · ROCE 18.3% · Operating margin 1.4% · 76% evidence Valuation 15.5/20 · P/E 21× · PEG 0.54 · 65% evidence Relative strength 11.5/20 · Lead over its industry -0.7% · Lead over S&P 500 2.2% · 1 year -1.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.7 + 14.9 + 15.5 + 11.5 = 61.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) CAH · turning · Evidence leans up · 85% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.2% · Profit 9.8% · Operating margin change 0.2 points · 95% evidence Capital efficiency 15.9/25 · ROCE 24.5% · Operating margin 1.3% · 76% evidence Valuation 5.0/20 · P/E 32.5× · PEG 2.72 · 65% evidence Relative strength 15.8/20 · Lead over its industry 8.5% · Lead over S&P 500 11.7% · 1 year 28.6% · 100% evidence · 7 of 12 weeks ahead Exact sum: 20.9 + 15.9 + 5 + 15.8 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) HSIC · turning · Evidence leans down · 85% evidence 45.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit 6% · Operating margin change 0.4 points · 95% evidence Capital efficiency 12.6/25 · ROCE 9.9% · Operating margin 5.8% · 76% evidence Valuation 7.3/20 · P/E 24× · PEG 2.33 · 65% evidence Relative strength 10.5/20 · Lead over its industry 0.1% · Lead over S&P 500 3.3% · 1 year 22.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.6 + 12.6 + 7.3 + 10.5 = 45 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) AHG · basing · Too little evidence to rank firmly · 51% evidence 35.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue n/a · Profit n/a · Operating margin change 5.6 points · 26% evidence Capital efficiency 4.8/25 · ROCE -2.2% · Operating margin -37.5% · 76% evidence Valuation 9.5/20 · P/E 25.6× · PEG n/a · 15% evidence Relative strength 4.4/20 · Lead over its industry -18.1% · Lead over S&P 500 -17.1% · 1 year -15.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.2 + 4.8 + 9.5 + 4.4 = 35.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. EDAP TMS S.A. FOCL · quiet · Most evidence points down · 67% evidence 28.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 7.1% · Profit n/a · Operating margin change 8.8 points · 71% evidence Capital efficiency 3.0/25 · ROCE -71.4% · Operating margin -60.8% · 76% evidence Valuation 8.5/20 · P/E 71.3× · PEG n/a · 15% evidence Relative strength 3.2/20 · Lead over its industry -3.1% · Lead over S&P 500 -0.7% · 1 year 114.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.2 + 3 + 8.5 + 3.2 = 28.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Empro Group Inc. EMPG · Too little evidence to rank firmly · 16% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/43.75 · Revenue n/a · Profit n/a · Operating margin change 65.6 points · 5% evidence Capital efficiency 21.6/31.25 · ROCE 39.6% · Operating margin 36.1% · 57% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 22.7 + 21.6 + 12.5 = 56.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. Accendra Health, Inc. ACH · Too little evidence to rank firmly · 38% evidence 36.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/43.75 · Revenue n/a · Profit n/a · Operating margin change -8.7 points · 45% evidence Capital efficiency 8.6/31.25 · ROCE 4.3% · Operating margin -1.5% · 76% evidence Valuation 14.4/25 · P/E -35.7× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 13.7 + 8.6 + 14.4 = 36.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Distribution](https://www.sectoralpha.in/us/sectors/medical-distribution), all 8 compared on one page. ## Which companies are close to McKesson in size? McKesson is the largest of 6 Medical Distribution companies on Sector Alpha by market value (scores of 4 November 2026). It is the largest. Just below it: Cencora, Inc., Cardinal Health, Inc., Henry Schein, Inc., Akso Health Group and EDAP TMS S.A. ### Medical Distribution companies close in size

1. McKesson Corporation $124.7 billion
2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) $67.6 billion
3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) $60.6 billion
4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) $9.8 billion
5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) $1.1 billion
6. [EDAP TMS S.A.](https://www.sectoralpha.in/us/stocks/focl) $199 million

[All 6 Medical Distribution companies, largest first](https://www.sectoralpha.in/us/sectors/medical-distribution#all-companies)

### Companies close in size in other industries

1. [HDFC Bank Limited](https://www.sectoralpha.in/us/stocks/hdb) $127 billion · Banks - Regional
2. [Starbucks Corporation](https://www.sectoralpha.in/us/stocks/sbux) $125.1 billion · Restaurants
3. McKesson Corporation $124.7 billion
4. [Capital One Financial Corporation](https://www.sectoralpha.in/us/stocks/cof) $124.1 billion · Credit Services
5. [Bank of Montreal](https://www.sectoralpha.in/us/stocks/bmo) $123.5 billion · Banks - Diversified

## What else do people ask about McKesson? ### What is McKesson's stock price today? McKesson Corporation's stock price is $1,069, +25.5% over the past year. The whole company is worth $125 B on the market. It is at its highest price of the past 52 weeks (range $736 to $1,069), 23.5% above its 200-day average. The price has been rising for 17 weeks (as of 4 November 2026). ### What were McKesson's latest quarterly results? McKesson Corporation reported revenue of $105 B and net profit of $1.0 B for the Jun 2026 quarter. Revenue rose 7.7% and profit rose 24.2% compared with a year earlier. Earnings per share were $5.15. The operating margin was 1.3%, 0.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is McKesson's market cap? McKesson Corporation's market capitalisation is $125 B at a stock price of $1,069. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is McKesson performing? McKesson Corporation's share price has been rising for 17 weeks. In its latest quarter, revenue rose 7.7% and profit rose 24.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running (as of 4 November 2026). ### Will McKesson's stock price go up? This page does not forecast McKesson Corporation's stock price. What it shows instead: the stock price is $1,069, and it has been rising for 17 weeks. Its P/E of 28.5× is higher than 83% of its own last 5 years (as of 4 November 2026). ### Where is McKesson in its business cycle? McKesson Corporation's FY26 operating margin was 1.6%, against a 5-year range of 1.4% to 1.6%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 1.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the McKesson story? The main question: results are strong, and the P/E is higher than 83% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is McKesson a stock worth studying right now? What the numbers show: McKesson Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.